Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
In late pregnancy, maternal serum 25(OH)D levels were higher in the intervention group than in the placebo group (Table 1).
Source: Cohort characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial
Source: Article title.
Within the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS) double‐blind, randomized placebo‐controlled trial, we examined the relationship of maternal vitamin D supplementation during pregnancy with offspring atopic eczema at ages 12, 24 and 48 months.
Source: Abstract.
In MAVIDOS, pregnant women were allocated to either cholecalciferol 1000 IU per day or matched placebo, taken from around 14 weeks’ gestation until delivery, with the primary outcome of neonatal whole‐body bone mineral content.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial
Randomised controlled trial · The British Journal of Dermatology · 2022
Original publication title
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial
© 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To examine the influence of maternal cholecalciferol supplementation during pregnancy on the risk of atopic eczema in the offspring at ages 12, 24 and 48 months.
Source: ObjectivesAbstract: What methods does the paper describe?
Within the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS) double‐blind, randomized placebo‐controlled trial, we examined the relationship of maternal vitamin D supplementation during pregnancy with offspring atopic eczema at ages 12, 24 and 48 months. In MAVIDOS, pregnant women were allocated to either cholecalciferol 1000 IU per day or matched placebo, taken from around 14 weeks’ gestation until delivery, with the primary outcome of neonatal whole‐body bone mineral content. The prevalence of atopic eczema in the offspring was ascertained at ages 12 (n = 635), 24 (n = 610) and 48 (n = 449) months, based on the UK Working Party criteria for the definition of atopic dermatitis.
The trial was registered with ISRCTN (82927713) and EudraCT (2007‐001716‐23).
Source: MethodsAbstract: Results
The characteristics of mothers and offspring were similar between the intervention and placebo groups, apart from longer breastfeeding duration in the intervention group. Adjusting for breastfeeding duration, offspring of mothers who received cholecalciferol 1000 IU daily had a lower odds ratio (OR) of atopic eczema at age 12 months [OR 0·55, 95% confidence interval (CI) 0·32 to 0·97, P = 0·04]; this effect weakened and was not statistically significant at ages 24 months (OR 0·76, 95% CI 0·47 to 1·23) or 48 months (OR 0·75, 95% CI 0·37 to 1·52).
The statistical interaction of intervention and breastfeeding duration in relation to eczema at age 12 months was not significant (P = 0·41), but stratification showed reduced infantile eczema risk in the intervention group for infants breastfed for ≥ 1 month (OR 0·48, 95% CI 0·24 to 0·94, P = 0·03) but not in those breastfed for < 1 month (OR 0·80, 95% CI 0·29 to 2·17, P = 0·66).
Source: ResultsAbstract: Conclusions
Our data provide the first randomized controlled trial evidence of a protective effect of antenatal cholecalciferol supplementation on the risk of infantile atopic eczema, with the effect potentially being via increased breast milk cholecalciferol levels. The findings support a developmental influence on atopic eczema, and point to a potentially modifiable perinatal influence on atopic eczema.
Source: ConclusionsAuthors’ abstract
Summary
Background
Evidence linking prenatal maternal vitamin D supplementation with the offspring’s risk of atopic eczema is inconsistent, with most data coming from observational studies.
Objectives
To examine the influence of maternal cholecalciferol supplementation during pregnancy on the risk of atopic eczema in the offspring at ages 12, 24 and 48 months.
Methods
Within the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS) double‐blind, randomized placebo‐controlled trial, we examined the relationship of maternal vitamin D supplementation during pregnancy with offspring atopic eczema at ages 12, 24 and 48 months. In MAVIDOS, pregnant women were allocated to either cholecalciferol 1000 IU per day or matched placebo, taken from around 14 weeks’ gestation until delivery, with the primary outcome of neonatal whole‐body bone mineral content. The prevalence of atopic eczema in the offspring was ascertained at ages 12 (n = 635), 24 (n = 610) and 48 (n = 449) months, based on the UK Working Party criteria for the definition of atopic dermatitis.
The trial was registered with ISRCTN (82927713) and EudraCT (2007‐001716‐23).
Results
The characteristics of mothers and offspring were similar between the intervention and placebo groups, apart from longer breastfeeding duration in the intervention group. Adjusting for breastfeeding duration, offspring of mothers who received cholecalciferol 1000 IU daily had a lower odds ratio (OR) of atopic eczema at age 12 months [OR 0·55, 95% confidence interval (CI) 0·32 to 0·97, P = 0·04]; this effect weakened and was not statistically significant at ages 24 months (OR 0·76, 95% CI 0·47 to 1·23) or 48 months (OR 0·75, 95% CI 0·37 to 1·52).
The statistical interaction of intervention and breastfeeding duration in relation to eczema at age 12 months was not significant (P = 0·41), but stratification showed reduced infantile eczema risk in the intervention group for infants breastfed for ≥ 1 month (OR 0·48, 95% CI 0·24 to 0·94, P = 0·03) but not in those breastfed for < 1 month (OR 0·80, 95% CI 0·29 to 2·17, P = 0·66).
Conclusions
Our data provide the first randomized controlled trial evidence of a protective effect of antenatal cholecalciferol supplementation on the risk of infantile atopic eczema, with the effect potentially being via increased breast milk cholecalciferol levels. The findings support a developmental influence on atopic eczema, and point to a potentially modifiable perinatal influence on atopic eczema.
What is already known about this topic?
There are currently no antenatal interventions proven to reduce the incidence of infantile atopic eczema in the general population.
However, observational studies have led to speculation that antenatal vitamin D supplementation may be beneficial.
Publication and source details
Original title: Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial
Sarah El‐Heis; Stefania D’Angelo; Elizabeth M. Curtis; Eugene Healy; Rebecca J. Moon; Sarah R. Crozier; Hazel Inskip; Cyrus Cooper; Nicholas C. Harvey; Keith M. Godfrey; the MAVIDOS Trial Group
The British Journal of Dermatology · 2022
* Correspondence:Keith Godfrey.
Email: kmg@mrc.soton.ac.uk
© 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Arthritis Research UK 10.13039/50110000034117702Biotechnology and Biological Sciences Research Council 10.13039/501100000268HDHL‐Biomarkers, BB/P028179/1Bupa Foundation 10.13039/501100000355Horizon 2020 Framework Programme 10.13039/100010661696295IHR Southampton 1000DaysPlus Global Nutrition Research GroupMedical Research Council 10.13039/5011000002654050502589MC_UU_12011/4programme code U105960371NIHR Musculoskeletal Biomedical Research UnitNIHR Southampton Biomedical Research CentreSeventh Framework Programme 10.13039/100011102FP7/2007‐2013University Hospital Southampton NHS Foundation Trust 10.13039/100010417University of Southampton 10.13039/501100000739
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T03:49:20.953593+00:00
DOI: 10.1111/bjd.21721 · PMC9804289